Loss of beta-catenin expression in metastatic gastric cancer

Matthias P A Ebert, Jun Yu, Juliane Hoffmann, Alba Rocco, Christoph Röcken, Sabine Kahmann, Oliver Müller, Murray Korc, Joseph J. Sung, Peter Malfertheiner

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Purpose: Beta-catenin (β-catenin) participates in intercellular adhesion and is an integral part of the Wnt signaling pathway. The role of β-catenin in the pathogenesis of gastric cancer and its metastasis is largely unknown. Patients and Methods: Immunohistochemistry and Western blot analysis were used to analyze the expression of β-catenin in 87 human gastric cancers, in metastasis and cancer cell lines. The β-catenin and the adenomatous polyposis coli (APC) genes were analyzed for gene mutations. Furthermore, methylation of the β-catenin promoter in cell lines was assessed by treatment with 5′-azadeoxycytidine and sodium bisulfite genomic sequencing. Results: β-Catenin expression was present at either the cell membrane or the cytoplasm in 34 of 75 primary gastric cancers. Expression of β-catenin was significantly more frequent in intestinal-type (P = .0049) and well-differentiated gastric cancers (P <.001). There were no quantitative differences between gastric cancers and the nonmalignant gastric tissues, as determined by Western blot analysis. One of 18 metastatic cancer lesions and four of five gastric cancer cell lines expressed β-catenin protein. N87 cells, derived from the liver metastasis of a gastric cancer, did not express β-catenin. Treatment with 5′-azadeoxycytidine restored β-catenin protein levels in this cell line, which exhibited significantly more 5-methylcytosines in the β-catenin promoter compared with the other cell lines. Conclusion: β-Catenin expression is lost in a subgroup of primary gastric cancers, is frequently absent in metastases, and exhibits nuclear localization in cancers with either β-catenin or APC gene mutations. Interestingly, the loss of β-catenin expression in metastatic gastric cancers may result from hypermethylation of the β-catenin promoter.

Original languageEnglish (US)
Pages (from-to)1708-1714
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Catenins
beta Catenin
Stomach Neoplasms
decitabine
Cell Line
APC Genes
Neoplasm Metastasis
Western Blotting
5-Methylcytosine
Neoplasms
Mutation
Wnt Signaling Pathway
Methylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ebert, M. P. A., Yu, J., Hoffmann, J., Rocco, A., Röcken, C., Kahmann, S., ... Malfertheiner, P. (2003). Loss of beta-catenin expression in metastatic gastric cancer. Journal of Clinical Oncology, 21(9), 1708-1714. https://doi.org/10.1200/JCO.2003.10.017

Loss of beta-catenin expression in metastatic gastric cancer. / Ebert, Matthias P A; Yu, Jun; Hoffmann, Juliane; Rocco, Alba; Röcken, Christoph; Kahmann, Sabine; Müller, Oliver; Korc, Murray; Sung, Joseph J.; Malfertheiner, Peter.

In: Journal of Clinical Oncology, Vol. 21, No. 9, 01.05.2003, p. 1708-1714.

Research output: Contribution to journalArticle

Ebert, MPA, Yu, J, Hoffmann, J, Rocco, A, Röcken, C, Kahmann, S, Müller, O, Korc, M, Sung, JJ & Malfertheiner, P 2003, 'Loss of beta-catenin expression in metastatic gastric cancer', Journal of Clinical Oncology, vol. 21, no. 9, pp. 1708-1714. https://doi.org/10.1200/JCO.2003.10.017
Ebert MPA, Yu J, Hoffmann J, Rocco A, Röcken C, Kahmann S et al. Loss of beta-catenin expression in metastatic gastric cancer. Journal of Clinical Oncology. 2003 May 1;21(9):1708-1714. https://doi.org/10.1200/JCO.2003.10.017
Ebert, Matthias P A ; Yu, Jun ; Hoffmann, Juliane ; Rocco, Alba ; Röcken, Christoph ; Kahmann, Sabine ; Müller, Oliver ; Korc, Murray ; Sung, Joseph J. ; Malfertheiner, Peter. / Loss of beta-catenin expression in metastatic gastric cancer. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 9. pp. 1708-1714.
@article{067d43f2ed0f494189cada4a5a4808c3,
title = "Loss of beta-catenin expression in metastatic gastric cancer",
abstract = "Purpose: Beta-catenin (β-catenin) participates in intercellular adhesion and is an integral part of the Wnt signaling pathway. The role of β-catenin in the pathogenesis of gastric cancer and its metastasis is largely unknown. Patients and Methods: Immunohistochemistry and Western blot analysis were used to analyze the expression of β-catenin in 87 human gastric cancers, in metastasis and cancer cell lines. The β-catenin and the adenomatous polyposis coli (APC) genes were analyzed for gene mutations. Furthermore, methylation of the β-catenin promoter in cell lines was assessed by treatment with 5′-azadeoxycytidine and sodium bisulfite genomic sequencing. Results: β-Catenin expression was present at either the cell membrane or the cytoplasm in 34 of 75 primary gastric cancers. Expression of β-catenin was significantly more frequent in intestinal-type (P = .0049) and well-differentiated gastric cancers (P <.001). There were no quantitative differences between gastric cancers and the nonmalignant gastric tissues, as determined by Western blot analysis. One of 18 metastatic cancer lesions and four of five gastric cancer cell lines expressed β-catenin protein. N87 cells, derived from the liver metastasis of a gastric cancer, did not express β-catenin. Treatment with 5′-azadeoxycytidine restored β-catenin protein levels in this cell line, which exhibited significantly more 5-methylcytosines in the β-catenin promoter compared with the other cell lines. Conclusion: β-Catenin expression is lost in a subgroup of primary gastric cancers, is frequently absent in metastases, and exhibits nuclear localization in cancers with either β-catenin or APC gene mutations. Interestingly, the loss of β-catenin expression in metastatic gastric cancers may result from hypermethylation of the β-catenin promoter.",
author = "Ebert, {Matthias P A} and Jun Yu and Juliane Hoffmann and Alba Rocco and Christoph R{\"o}cken and Sabine Kahmann and Oliver M{\"u}ller and Murray Korc and Sung, {Joseph J.} and Peter Malfertheiner",
year = "2003",
month = "5",
day = "1",
doi = "10.1200/JCO.2003.10.017",
language = "English (US)",
volume = "21",
pages = "1708--1714",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Loss of beta-catenin expression in metastatic gastric cancer

AU - Ebert, Matthias P A

AU - Yu, Jun

AU - Hoffmann, Juliane

AU - Rocco, Alba

AU - Röcken, Christoph

AU - Kahmann, Sabine

AU - Müller, Oliver

AU - Korc, Murray

AU - Sung, Joseph J.

AU - Malfertheiner, Peter

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Purpose: Beta-catenin (β-catenin) participates in intercellular adhesion and is an integral part of the Wnt signaling pathway. The role of β-catenin in the pathogenesis of gastric cancer and its metastasis is largely unknown. Patients and Methods: Immunohistochemistry and Western blot analysis were used to analyze the expression of β-catenin in 87 human gastric cancers, in metastasis and cancer cell lines. The β-catenin and the adenomatous polyposis coli (APC) genes were analyzed for gene mutations. Furthermore, methylation of the β-catenin promoter in cell lines was assessed by treatment with 5′-azadeoxycytidine and sodium bisulfite genomic sequencing. Results: β-Catenin expression was present at either the cell membrane or the cytoplasm in 34 of 75 primary gastric cancers. Expression of β-catenin was significantly more frequent in intestinal-type (P = .0049) and well-differentiated gastric cancers (P <.001). There were no quantitative differences between gastric cancers and the nonmalignant gastric tissues, as determined by Western blot analysis. One of 18 metastatic cancer lesions and four of five gastric cancer cell lines expressed β-catenin protein. N87 cells, derived from the liver metastasis of a gastric cancer, did not express β-catenin. Treatment with 5′-azadeoxycytidine restored β-catenin protein levels in this cell line, which exhibited significantly more 5-methylcytosines in the β-catenin promoter compared with the other cell lines. Conclusion: β-Catenin expression is lost in a subgroup of primary gastric cancers, is frequently absent in metastases, and exhibits nuclear localization in cancers with either β-catenin or APC gene mutations. Interestingly, the loss of β-catenin expression in metastatic gastric cancers may result from hypermethylation of the β-catenin promoter.

AB - Purpose: Beta-catenin (β-catenin) participates in intercellular adhesion and is an integral part of the Wnt signaling pathway. The role of β-catenin in the pathogenesis of gastric cancer and its metastasis is largely unknown. Patients and Methods: Immunohistochemistry and Western blot analysis were used to analyze the expression of β-catenin in 87 human gastric cancers, in metastasis and cancer cell lines. The β-catenin and the adenomatous polyposis coli (APC) genes were analyzed for gene mutations. Furthermore, methylation of the β-catenin promoter in cell lines was assessed by treatment with 5′-azadeoxycytidine and sodium bisulfite genomic sequencing. Results: β-Catenin expression was present at either the cell membrane or the cytoplasm in 34 of 75 primary gastric cancers. Expression of β-catenin was significantly more frequent in intestinal-type (P = .0049) and well-differentiated gastric cancers (P <.001). There were no quantitative differences between gastric cancers and the nonmalignant gastric tissues, as determined by Western blot analysis. One of 18 metastatic cancer lesions and four of five gastric cancer cell lines expressed β-catenin protein. N87 cells, derived from the liver metastasis of a gastric cancer, did not express β-catenin. Treatment with 5′-azadeoxycytidine restored β-catenin protein levels in this cell line, which exhibited significantly more 5-methylcytosines in the β-catenin promoter compared with the other cell lines. Conclusion: β-Catenin expression is lost in a subgroup of primary gastric cancers, is frequently absent in metastases, and exhibits nuclear localization in cancers with either β-catenin or APC gene mutations. Interestingly, the loss of β-catenin expression in metastatic gastric cancers may result from hypermethylation of the β-catenin promoter.

UR - http://www.scopus.com/inward/record.url?scp=0038135028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038135028&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.10.017

DO - 10.1200/JCO.2003.10.017

M3 - Article

C2 - 12721245

AN - SCOPUS:0038135028

VL - 21

SP - 1708

EP - 1714

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -